Ryan Crowe
Contatto Relazioni con gli Investitori presso REGENERON PHARMACEUTICALS, INC.
Profilo
Ryan Crowe is currently the Head of Investor Relations at Regeneron Pharmaceuticals, Inc. Prior to this, he worked as the Senior Director of Investor Relations at Pfizer Inc. and as the Vice President of Investor Relations at Myovant Sciences Ltd.
He received his undergraduate degree from Drexel University and his MBA from The Leonard N Stern School of Business.
Posizioni attive di Ryan Crowe
| Società | Posizione | Inizio |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | - |
Precedenti posizioni note di Ryan Crowe
| Società | Posizione | Fine |
|---|---|---|
| MYOVANT SCIENCES LTD. | Contatto Relazioni con gli Investitori | - |
| PFIZER, INC. | Public Communications Contact | - |
Formazione di Ryan Crowe
| Drexel University | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Ryan Crowe
